Review
Management of disseminated disease in the patient with bladder cancer
Affiliations
- PMID: 7974898
Item in Clipboard
Review
Management of disseminated disease in the patient with bladder cancer
Urol Clin North Am.
1994 Nov.
Abstract
Advanced transitional cell carcinoma of the bladder is a chemotherapy-sensitive neoplasm. Several single agents demonstrate substantial activity, and combination chemotherapy produces responses in the majority of patients treated. The benefits and toxicities associated with the most widely used combination regimens are discussed. Other topics reviewed include the use of colony-stimulating factor support for chemotherapy, adjunctive surgical therapy, and newer cytotoxic regimens.
Similar articles
-
Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.Can J Urol. 2002 Oct;9(5):1625-33. Can J Urol. 2002. PMID: 12431323
-
Adjuvant and neoadjuvant chemotherapy for urothelial carcinoma.Surg Oncol Clin N Am. 1997 Oct;6(4):667-81. Surg Oncol Clin N Am. 1997. PMID: 9309087 Review.
-
Current status of chemotherapy for urothelial tract tumors.Oncology (Williston Park). 1987 Jul;1(5):41-50, 60. Oncology (Williston Park). 1987. PMID: 3079483 Review.
-
Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-68-S15-71. Semin Oncol. 1997. PMID: 9346226 Clinical Trial.
-
Adjunctive adjuvant or neoadjuvant chemotherapy for locally advanced bladder cancer: a critical appraisal of the present status.Semin Urol. 1993 Nov;11(4):227-34. Semin Urol. 1993. PMID: 8290828 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical